The Math Behind the Aftermath Driving a Private-Public Merger Transaction: Mast Therapeutics and Savara

The Math Behind the Aftermath Driving a Private-Public Merger Transaction: Mast Therapeutics and Savara

Objective Capital’s Dr. David Crean to Moderate M&A

Panel Discussion for ACG San Diego on June 20, 2017

San Diego, CA- June 6, 2017 – Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as Moderator for ACG San Diego’s Hot Topics in Life Sciences M&A, June 20, 2017 at Lomas Santa Fe Country Club, Solana Beach, CA from 7-9 AM.

The panel discussion will focus on the recent M&A transaction between Mast Therapeutics, Inc. (NYSE MKT: MSTX), a publicly held biotechnology company based in San Diego, CA, and privately-held emerging specialty pharmaceutical company, Savara Inc. The panel discussion will focus on why it made sense to merge a public company with privately-held, emerging specialty pharmaceutical company following Mast’s failed phase 3 program in sickle cell disease instead of further R&D investments and pursuing a phase 2 pipeline compound.

Dr. Crean will moderate the panel discussion involving Brian Cully, CEO and Director of Mast Therapeutics, and Larry Nishnick, Partner, Corporate & Securities Practice at DLA Piper LLP (US).  The panel will provide frank perspectives on the transaction, the math behind the analysis following the phase 3 failure and insight so that the audience might find relevance in their own work and highlight points of differentiation explaining why the merger wasn’t just plain “vanilla”. Merging was the best outcome for shareholders, relative to risking further loss.

For more information about the ACG San Diego event and to register, please visit or contact Executive Director, AG San Diego, Judy Susser-Travis at or 619-741-7247.

About ACG San Diego

Founded in 1954, the Association for Corporate Growth (ACG) has chapters worldwide representing 14,500 members. ACG serves 90,000 investors, executives, lenders and advisers to growing middle-market companies. ACG’s mission is to drive middle-market growth. For more information, visit

About Objective Capital Partners

Objective Capital Partners is a leading M&A investment banking firm whose Principals have collectively engaged in more than 500 successful transactions serving the transaction needs of growth stage and mid-size companies. The executive team has a unique combination of investment banking, private equity, and business ownership experience that enables Objective Capital Partners to provide large enterprise caliber investment banking services to companies.  The firm focuses on middle market M&A and capital raise activities for companies with enterprise values between $10-100 million, healthcare & life sciences and valuation advisory services. The firm’s industry expertise includes: software and hardware technology, life sciences, business services, IT services, healthcare services, biotech, consumer products and specialized manufacturing. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Dr. Crean and other Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities. Additional information on Objective Capital Partners is available at


This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

# # #



Mandy F. Woods

Business Office Manager

Objective Capital Partners

Tel: 858-208-3442


man looking at notes on stage

Objective Capital’s Dr. David Crean to Judge Life Sciences Company Pitches at Start-Up Stadium 2017


I would like more information about...

Connect With Us